Incivek

Incivek is a brand name of telaprevir, approved by the FDA in the following formulation(s):

INCIVEK (telaprevir - tablet; oral)

• 
  Manufacturer: VERTEX PHARMS
  
  Approval date: May 23, 2011
  
  Strength(s): 375MG ^[RLD]

Has a generic version of Incivek been approved?

No. There is currently no therapeutically equivalent version of Incivek available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Incivek. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Peptidomimetic protease inhibitors
  Patent 7,820,671
  Issued: October 26, 2010
  Inventor(s): Babine; Robert Edward & Chen; Shu Hui & Collado; Ivan & Garcia-Paredes; Cristina & Glass; John Irvin & Guo; Deqi & Jin; Ling & Lamar; Jason Eric & Parker, III; Raymond Samuel & Snyder; Nancy June & Sun; Xicheng David & Tebbe; Mark Joseph & Victor; Frantz & Wang; Q. May & Yip; Yvonne
  Assignee(s): Vertex Pharmaceuticals Incorporated
  The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
  
  Patent expiration dates:
  
  
  • February 25, 2025
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 23, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Incivek Consumer Information (Drugs.com)
• Incivek Consumer Information (Wolters Kluwer)
• Incivek Consumer Information (Cerner Multum)
• Incivek Advanced Consumer Information (Micromedex)
• Telaprevir Consumer Information (Wolters Kluwer)
• Telaprevir Consumer Information (Cerner Multum)
• Telaprevir Advanced Consumer Information (Micromedex)